Overview
INBX market data
Price History
INBX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$9.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.06 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,465.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $20.57 – $155.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.4B · P/B 143.75 · P/S 975.74.
Company News
Inhibrx Biosciences Q2 EPS $(2.34) Beats $(2.39) EstimateBenzinga · Aug 13, 2026, 8:35 PM
8-K filing — Inhibrx Biosciences, Inc. (INBX)SEC EDGAR · Aug 13, 2026, 8:10 PM
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027Benzinga · Jun 15, 2026, 1:25 PM
Inhibrx Biosciences shares are trading lower after the company reported worse-than-expected Q1 EPS results.Benzinga · May 15, 2026, 3:53 PM
Inhibrx Reports First Quarter 2026 Financial ResultsBenzinga · May 14, 2026, 9:15 PM
Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) EstimateBenzinga · May 14, 2026, 8:38 PM